EGFR and non-small cell lung carcinoma: Consequently, this methodology is more suitable for the detection of activating known mutations in NSCLC (e.g., EGFR mutations) or hotspot resistance mutations to tyrosine kinase inhibitors (e.g., ALK C1156Y, I1171N or EGFR C797X) [45,46,47].